Articles with public access mandates - Mustafa KhasrawLearn more
Not available anywhere: 8
Geographic region, socioeconomic position and the utilisation of primary total joint replacement for hip or knee osteoarthritis across western Victoria: a cross-sectional …
S Brennan-Olsen, S Vogrin, KL Holloway, RS Page, MA Sajjad, ...
Archives of osteoporosis 12, 1-7, 2017
Mandates: National Health and Medical Research Council, Australia
Cetuximab alone or with irinotecan for resistant KRAS-, NRAS-, BRAF-and PIK3CA-wild-type metastatic colorectal cancer: the AGITG randomized phase II ICECREAM study
JD Shapiro, S Thavaneswaran, CR Underhill, KP Robledo, CS Karapetis, ...
Clinical colorectal cancer 17 (4), 313-319, 2018
Mandates: National Health and Medical Research Council, Australia
The epidemiology of emergency presentations for falls from height across Western Victoria, Australia
KL Holloway-Kew, TR Baker, MA Sajjad, MA Kotowicz, PM Livingston, ...
Australasian emergency care 23 (2), 119-125, 2020
Mandates: National Health and Medical Research Council, Australia
Retrospective analysis of cancer survival across S outh‐W estern V ictoria in A ustralia
SF Wong, L Matheson, K Morrissy, G Pitson, DM Ashley, M Khasraw, ...
Australian Journal of Rural Health 24 (2), 79-84, 2016
Mandates: National Health and Medical Research Council, Australia
Advances in Treatment of Isocitrate Dehydrogenase (IDH)-Wildtype Glioblastomas
HW Sim, S Lorrey, M Khasraw
Current Neurology and Neuroscience Reports 23 (6), 263-276, 2023
Mandates: US National Institutes of Health
Phase II trial of continuous low-dose temozolomide (TMZ) for recurrent malignant glioma (MG) with and without prior exposure to bevacizumab (BEV).
M Khasraw, LE Abrey, AB Lassman, A Hormigo, C Nolan, IT Gavrilovic, ...
Journal of Clinical Oncology 28 (15_suppl), 2065-2065, 2010
Mandates: US National Institutes of Health
The Epidemiology of Joint Replacements Across Western Victoria, Australia: a Cross-sectional Study
KL Holloway-Kew, MA Sajjad, MA Kotowicz, S Graves, A Cuthbert, ...
SN Comprehensive Clinical Medicine 1, 1038-1047, 2019
Mandates: National Health and Medical Research Council, Australia
P01. 035 Nivolumab and Temozolomide (TMZ) vs TMZ alone in newly diagnosed elderly patients (pts) with Glioblastoma (GBM)(NUTMEG): Trial in progress
M Khasraw, K McDonald, S Yip, RG Verhaak, AB Heimberger, M Hall, ...
Neuro-oncology 20 (Suppl 3), iii236, 2018
Mandates: National Health and Medical Research Council, Australia
Available somewhere: 71
High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types
DJ McGrail, PG Pilié, NU Rashid, L Voorwerk, M Slagter, M Kok, ...
Annals of Oncology 32 (5), 661-672, 2021
Mandates: US National Institutes of Health, Cancer Prevention Research Institute of …
Longitudinal molecular trajectories of diffuse glioma in adults
FP Barthel, KC Johnson, FS Varn, AD Moskalik, G Tanner, E Kocakavuk, ...
Nature 576 (7785), 112-120, 2019
Mandates: US National Institutes of Health, Austrian Science Fund, National Health and …
Tumor mutational burden as a predictor of immunotherapy response: is more always better?
JH Strickler, BA Hanks, M Khasraw
Clinical Cancer Research 27 (5), 1236-1241, 2021
Mandates: US National Institutes of Health
Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized …
A Omuro, AA Brandes, AF Carpentier, A Idbaih, DA Reardon, ...
Neuro-oncology 25 (1), 123-134, 2023
Mandates: US National Institutes of Health
Glioma progression is shaped by genetic evolution and microenvironment interactions
FS Varn, KC Johnson, J Martinek, JT Huse, MLP Nasrallah, P Wesseling, ...
Cell 185 (12), 2184-2199. e16, 2022
Mandates: Fundação de Amparo à Pesquisa do Estado de São Paulo, US Department of …
Adaptive global innovative learning environment for glioblastoma: GBM AGILE
BM Alexander, S Ba, MS Berger, DA Berry, WK Cavenee, SM Chang, ...
Clinical Cancer Research 24 (4), 737-743, 2018
Mandates: US National Institutes of Health, Wellcome Trust
Antiangiogenic therapy for high‐grade glioma
M Khasraw, MS Ameratunga, R Grant, H Wheeler, N Pavlakis
Cochrane Database of Systematic Reviews, 2014
Mandates: National Institute for Health Research, UK
Anti‐angiogenic therapy for high‐grade glioma
M Ameratunga, N Pavlakis, H Wheeler, R Grant, J Simes, M Khasraw
Cochrane Database of Systematic Reviews, 2018
Mandates: National Institute for Health Research, UK
Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies
ST Garber, Y Hashimoto, SP Weathers, J Xiu, Z Gatalica, RGW Verhaak, ...
Neuro-oncology 18 (10), 1357-1366, 2016
Mandates: US National Institutes of Health
Glioma through the looking GLASS: molecular evolution of diffuse gliomas and the Glioma Longitudinal Analysis Consortium
Neuro-oncology 20 (7), 873-884, 2018
Mandates: US National Institutes of Health, Austrian Science Fund, National Health and …
MYCN amplification drives an aggressive form of spinal ependymoma
DR Ghasemi, M Sill, K Okonechnikov, A Korshunov, S Yip, PW Schutz, ...
Acta neuropathologica 138, 1075-1089, 2019
Mandates: Helmholtz Association, UK Medical Research Council, National Institute for …
Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma
A Omuro, TA Chan, LE Abrey, M Khasraw, AS Reiner, TJ Kaley, ...
Neuro-oncology 15 (2), 242-250, 2013
Mandates: US National Institutes of Health
Publication and funding information is determined automatically by a computer program